WE CLAIM:
1. Crystalline Form II of fosamprenavir calcium characterized by an XRPD pattern comprising interplanar spacing (d) values substantially at 15.98, 9.25, 8.02, 6.07, 5.35, 5.04, 2.86 and 2.70 (A).
2. Crystalline Form II of fosamprenavir calcium according to claim 1 characterized by an XRPD pattern comprising interplanar spacing (d) values substantially at 15.98, 9.25, 8.02, 6.47, 6.07, 5.35, 5.04, 4.61, 4.46, 4.35, 4.13, 4.07, 4.00, 3.69, 3.63, 3.51, 3.46, 3.42, 3.27, 3.18, 3.04, 2.93,2.89, 2.86,2.77, 2.70,2.63, 2.58, 2.53, 2.43,2.34 and 2.29 (A).
3. Crystalline Form II of fosamprenavir calcium having substantially the same FTIR pattern as depicted in Figure 5.
4. A process for the preparation of crystalline Form II of fosamprenavir calcium, wherein the process comprises:

a) dissolving fosamprenavir calcium in a water miscible organic solvent, wherein the water miscible organic solvent comprises a propanol,
b) treating the solution obtained in step a) with water and
c) isolating crystalline Form II of fosamprenavir calcium from the mixture thereof.

5. A process according to claim 4, wherein the water miscible organic solvent further comprises methanol, ethanol, or a mixture thereof.
6. A pharmaceutical composition comprising crystalline Form II of fosamprenavir calcium and a pharmaceutically acceptable carrier.
7. A method of treating HIV infection comprising a step of administering to a patient in need thereof a therapeutically effective amount of crystalline Form II of fosamprenavir calcium.